SMO mutation predicts the effect of immune checkpoint inhibitor: From NSCLC to multiple cancers

BACKGROUND: The emergence of immune checkpoint inhibitors (ICIs) is one of the most promising breakthroughs for the treatment of multiple cancer types, but responses vary. Growing evidence points to a link between developmental signaling pathway-related genes and antitumor immunity, but the associat...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Wenxiang, Niu, Xiaomin, Yu, Yongfeng, Li, Ziming, Gu, LinPing, Lu, Shun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669061/
https://www.ncbi.nlm.nih.gov/pubmed/36405701
http://dx.doi.org/10.3389/fimmu.2022.955800

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669061/
https://www.ncbi.nlm.nih.gov/pubmed/36405701
http://dx.doi.org/10.3389/fimmu.2022.955800

Ejemplares similares